Essex Woodlands Management, Inc.
Essex Woodlands Management, Inc. reported 5 US-listed holdings worth $254.2 million in its 13F for the quarter ended 30 June 2026, filed 4 August 2026. Its largest: Bioventus Inc. (48.3%), Mimedx Group Inc. (42.7%) and Eyepoint Pharmaceuticals Inc. (6.1%). Against the quarter before, it opened 0 positions, added to 0, trimmed 0 and sold out of 0.
The 5 largest of its 5 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned -27.4% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Bioventus Inc. BVS | 13.0M | $122.9 million | 48.35% | no change |
| Mimedx Group Inc. MDXG | 28.2M | $108.6 million | 42.70% | no change |
| Eyepoint Pharmaceuticals Inc. EYPT | 1.1M | $15.5 million | 6.10% | no change |
| Tela Bio Inc. TELA | 7.7M | $5.8 million | 2.28% | no change |
| Medicinova Inc. MNOV | 1.1M | $1.5 million | 0.57% | no change |